logo-loader
viewKazia Therapeutics Ltd

Kazia Therapeutics substantial shareholder lifts interest to 17.4%

Sydney-based Hishenk Pty Ltd now holds 10.835 million shares after placement and on-market purchases.

1562228321_shutterstock_560818570.jpg
Edison Investment Research assigned Kazia an indicative valuation range of A$1.35–2.17 per share

Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) substantial shareholder Hishenk Pty Ltd has reiterated its confidence in the biotechnology company’s oncology drug development by increasing its interest to 17.4% from 13.8%.

The holding of the Sydney-based investor was boosted to 10.835 million shares on June 26 with another 1.844 million shares accumulated.

Since October 3 last year Hishenk and related entities have participated in a placement and purchased shares on-market, increasing the holding from around 6.685 million shares.

Today Kazia traded up almost 4% to A$0.40.

READ: Kazia Therapeutics has two novel classes of anti-cancer drugs: Edison Investment Research

Edison Investment Research has recently assigned an indicative valuation range of A$84–135 million or A$1.35–2.17 per share for the company.

This follows identification of a higher maximum tolerated dose (MTD) from a Phase IIa study of its brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor GDC-0084 in glioblastoma (GBM).

The result may lead to improved efficacy in the ongoing expansion cohort and planned Phase IIb study.

READ: Kazia Therapeutics to collaborate with US-based oncology foundation on clinical trials for metastatic brain cancer treatment

GBM multiforme is the most common and aggressive form of primary brain cancer, with chemotherapy treatment temozolomide only effective in one-third of patients.

Furthermore, the median survival rate is 12-15 months from diagnosis, meaning there is demand in the market for superior treatments.

Kazia is developing GDC-0084, a brain penetrant PI3K inhibitor licensed from Genentech, and a third-generation benzopyran drug, Cantrixil.

A new collaboration with the Alliance for Clinical Trials in Oncology means Kazia will soon have four clinical trials of GDC-0084 underway in primary or secondary brain cancers.

Further data from the Cantrixil Phase I study in ovarian cancer expected in the second half of 2019.

Quick facts: Kazia Therapeutics Ltd

Price: 0.41 AUD

ASX:KZA
Market: ASX
Market Cap: $25.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Kazia Therapeutics presents new data from Cantrixil Phase 1...

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive on the company’s presentation of new data from the Cantrixil Phase 1 Study in Ovarian Cancer, at the European Society for Medical Oncology (ESMO) in Barcelona, Spain. The CEO also spoke about Kazia...

on 1/10/19

2 min read